
MannKind (MNKD) Stock Forecast & Price Target
MannKind (MNKD) Analyst Ratings
Bulls say
MannKind Corp's ongoing advancements in its orphan lung pipeline position the company for long-term diversification and growth, significantly enhancing its revenue potential. The management's targeted marketing strategies and educational campaigns are expected to boost uptake of their products, particularly Afrezza and Tyvaso DPI, across key therapeutic areas. Additionally, the company's efforts to secure approval for the Furoscix auto-injector could further solidify its standing as a valuable revenue driver, highlighting robust royalty income opportunities in pulmonary arterial hypertension and related indications.
Bears say
MannKind Corporation faces significant challenges following the announcement of a competing product to Furoscix, leading to a notable decline in stock price and raising concerns about the company's competitive positioning and market share. The potential for adverse trial outcomes or regulatory setbacks threatens to hinder the commercialization of its pipeline products, namely MNKD-102 and MNKD-201, as they aim to address unmet medical needs in lung diseases. Additionally, the presence of well-capitalized competitors with established products may further erode MannKind's market presence and limit pricing power, contributing to an overall negative outlook on the stock.
This aggregate rating is based on analysts' research of MannKind and is not a guaranteed prediction by Public.com or investment advice.
MannKind (MNKD) Analyst Forecast & Price Prediction
Start investing in MannKind (MNKD)
Order type
Buy in
Order amount
Est. shares
0 shares